Intravitreal injection of bevacizumab induces inflammatory alterations in a uveitis experimental model.
Johnsen-Soriano
Siv
S
Fundación Oftalmológica del Mediterráneo (FOM), Valencia, Spain.
Arnal
Emma
E
Sancho-Tello
María
M
Muriach
María
M
Almansa
Inmaculada
I
Bosch-Morell
Francisco
F
Navea
Amparo
A
Romero
Francisco J
FJ
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001082:Aqueous Humor / Q000378:metabolism*; D000068258:Bevacizumab; D018932:Chemokine CCL2 / Q000378:metabolism; D018946:Chemokine CCL5 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D007371:Interferon-gamma / Q000378:metabolism; D058449:Intravitreal Injections; D008070:Lipopolysaccharides; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D014605:Uveitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D016207:Cytokines; D008070:Lipopolysaccharides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007371:Interferon-gamma